Physician profile
Irwin Blau
NPI 1801869730
$10,901.70
in general payments reported to CMS, 2019-2025
55 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,630 · 2020: $1,143 · 2021: $3,098 · 2022: $1,856 · 2023: $1,807 · 2024: $921 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,580.78 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Medtronic, INC. | $1,487.88 | 2021-2025 | Linq II, Micra |
| Sk Life Science, INC. | $688.88 | 2020-2024 | |
| Amgen INC. | $616.11 | 2019-2024 | Uplizna |
| Genzyme Corporation | $560.31 | 2019-2023 | |
| Ucb, INC. | $436.92 | 2019-2022 | |
| Biogen, INC. | $394.39 | 2019-2023 | Tysabri, Vumerity |
| Neurocrine Biosciences, INC. | $371.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $306.86 | 2019-2021 | |
| Mdd US Operations, LLC | $251.76 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $230.62 | 2022 | |
| Alexion Pharmaceuticals, INC. | $220.53 | 2019-2023 | Soliris, Ultomiris |
| Mallinckrodt Hospital Products INC. | $191.17 | 2020-2021 | |
| Lundbeck LLC | $184.89 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $164.13 | 2019-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irwin Blau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.